Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-label Trial of Patients With Ulcerative Colitis.

Telesco SE, Brodmerkel C, Zhang H, Kim LL, Johanns J, Mazumder A, Li K, Baribaud F, Curran M, Strauss R, Paxson B, Plevy S, Davison T, Knight L, Dibben S, Schreiber S, Sandborn W, Rutgeerts P, Siegel CA, Reinisch W, Greenbaum L.

Gastroenterology. 2018 Jul 4. pii: S0016-5085(18)34719-X. doi: 10.1053/j.gastro.2018.06.077. [Epub ahead of print]

2.

Longitudinal Study of the Psoriasis-Associated Skin Microbiome during Therapy with Ustekinumab in a Randomized Phase 3b Clinical Trial.

Loesche MA, Farahi K, Capone K, Fakharzadeh S, Blauvelt A, Duffin KC, DePrimo SE, Muñoz-Elías EJ, Brodmerkel C, Dasgupta B, Chevrier M, Smith K, Horwinski J, Tyldsley A, Grice EA.

J Invest Dermatol. 2018 Mar 17. pii: S0022-202X(18)31731-7. doi: 10.1016/j.jid.2018.03.1501. [Epub ahead of print]

PMID:
29559344
3.

Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients.

Doherty MK, Ding T, Koumpouras C, Telesco SE, Monast C, Das A, Brodmerkel C, Schloss PD.

MBio. 2018 Mar 13;9(2). pii: e02120-17. doi: 10.1128/mBio.02120-17.

4.

Molecular Comparison of Adult and Pediatric Ulcerative Colitis Indicates Broad Similarity of Molecular Pathways in Disease Tissue.

Li K, Strauss R, Ouahed J, Chan D, Telesco SE, Shouval DS, Canavan JB, Brodmerkel C, Snapper SB, Friedman JR.

J Pediatr Gastroenterol Nutr. 2018 Jul;67(1):45-52. doi: 10.1097/MPG.0000000000001898.

PMID:
29401083
5.

A functional genomics predictive network model identifies regulators of inflammatory bowel disease.

Peters LA, Perrigoue J, Mortha A, Iuga A, Song WM, Neiman EM, Llewellyn SR, Di Narzo A, Kidd BA, Telesco SE, Zhao Y, Stojmirovic A, Sendecki J, Shameer K, Miotto R, Losic B, Shah H, Lee E, Wang M, Faith JJ, Kasarskis A, Brodmerkel C, Curran M, Das A, Friedman JR, Fukui Y, Humphrey MB, Iritani BM, Sibinga N, Tarrant TK, Argmann C, Hao K, Roussos P, Zhu J, Zhang B, Dobrin R, Mayer LF, Schadt EE.

Nat Genet. 2017 Oct;49(10):1437-1449. doi: 10.1038/ng.3947. Epub 2017 Sep 11.

PMID:
28892060
6.

Clinical efficacy and IL-17 targeting mechanism of Indigo naturalis as a topical agent in moderate psoriasis.

Cheng HM, Wu YC, Wang Q, Song M, Wu J, Chen D, Li K, Wadman E, Kao ST, Li TC, Leon F, Hayden K, Brodmerkel C, Chris Huang C.

BMC Complement Altern Med. 2017 Sep 2;17(1):439. doi: 10.1186/s12906-017-1947-1.

7.

Cathepsin-S degraded decorin are elevated in fibrotic lung disorders - development and biological validation of a new serum biomarker.

Kehlet SN, Bager CL, Willumsen N, Dasgupta B, Brodmerkel C, Curran M, Brix S, Leeming DJ, Karsdal MA.

BMC Pulm Med. 2017 Aug 9;17(1):110. doi: 10.1186/s12890-017-0455-x.

8.

Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, Coccia M, Görtz D, This S, Stockenhuber K, Pott J, Friedrich M, Ryzhakov G, Baribaud F, Brodmerkel C, Cieluch C, Rahman N, Müller-Newen G, Owens RJ, Kühl AA, Maloy KJ, Plevy SE; Oxford IBD Cohort Investigators, Keshav S, Travis SPL, Powrie F.

Nat Med. 2017 Jun 6;23(6):788. doi: 10.1038/nm0617-788d. No abstract available.

PMID:
28586341
9.

Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, Coccia M, Görtz D, This S, Stockenhuber K, Pott J, Friedrich M, Ryzhakov G, Baribaud F, Brodmerkel C, Cieluch C, Rahman N, Müller-Newen G, Owens RJ, Kühl AA, Maloy KJ, Plevy SE; Oxford IBD Cohort Investigators, Keshav S, Travis SPL, Powrie F.

Nat Med. 2017 May;23(5):579-589. doi: 10.1038/nm.4307. Epub 2017 Apr 3. Erratum in: Nat Med. 2017 Jun 6;23 (6):788.

10.

Sarcoidosis extent relates to molecular variability.

Monast CS, Li K, Judson MA, Baughman RP, Wadman E, Watt R, Silkoff PE, Barnathan ES, Brodmerkel C.

Clin Exp Immunol. 2017 Jun;188(3):444-454. doi: 10.1111/cei.12942. Epub 2017 Mar 27.

11.

High-Throughput Characterization of Blood Serum Proteomics of IBD Patients with Respect to Aging and Genetic Factors.

Di Narzo AF, Telesco SE, Brodmerkel C, Argmann C, Peters LA, Li K, Kidd B, Dudley J, Cho J, Schadt EE, Kasarskis A, Dobrin R, Hao K.

PLoS Genet. 2017 Jan 27;13(1):e1006565. doi: 10.1371/journal.pgen.1006565. eCollection 2017 Jan.

12.

HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program.

Li K, Huang CC, Randazzo B, Li S, Szapary P, Curran M, Campbell K, Brodmerkel C.

J Invest Dermatol. 2016 Dec;136(12):2364-2371. doi: 10.1016/j.jid.2016.06.631. Epub 2016 Jul 29.

13.

Correction: Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis Are Highly Related Diseases that Appear to Be Distinct from Psoriasis Vulgaris.

Bissonnette R, Suárez-Fariñas M, Li X, Bonifacio KM, Brodmerkel C, Fuentes-Duculan J, Krueger JG.

PLoS One. 2016 Jun 21;11(6):e0158190. doi: 10.1371/journal.pone.0158190. eCollection 2016.

14.

Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis Are Highly Related Diseases that Appear to Be Distinct from Psoriasis Vulgaris.

Bissonnette R, Suárez-Fariñas M, Li X, Bonifacio KM, Brodmerkel C, Fuentes-Duculan J, Krueger JG.

PLoS One. 2016 May 6;11(5):e0155215. doi: 10.1371/journal.pone.0155215. eCollection 2016. Erratum in: PLoS One. 2016;11(6):e0158190.

15.

Integrative genomic deconvolution of rheumatoid arthritis GWAS loci into gene and cell type associations.

Walsh AM, Whitaker JW, Huang CC, Cherkas Y, Lamberth SL, Brodmerkel C, Curran ME, Dobrin R.

Genome Biol. 2016 Apr 30;17:79. doi: 10.1186/s13059-016-0948-6.

16.

Variants in TRIM22 That Affect NOD2 Signaling Are Associated With Very-Early-Onset Inflammatory Bowel Disease.

Li Q, Lee CH, Peters LA, Mastropaolo LA, Thoeni C, Elkadri A, Schwerd T, Zhu J, Zhang B, Zhao Y, Hao K, Dinarzo A, Hoffman G, Kidd BA, Murchie R, Al Adham Z, Guo C, Kotlarz D, Cutz E, Walters TD, Shouval DS, Curran M, Dobrin R, Brodmerkel C, Snapper SB, Klein C, Brumell JH, Hu M, Nanan R, Snanter-Nanan B, Wong M, Le Deist F, Haddad E, Roifman CM, Deslandres C, Griffiths AM, Gaskin KJ, Uhlig HH, Schadt EE, Muise AM.

Gastroenterology. 2016 May;150(5):1196-1207. doi: 10.1053/j.gastro.2016.01.031. Epub 2016 Feb 4.

17.

Gene expression profiling of skin and blood in hidradenitis suppurativa.

Blok JL, Li K, Brodmerkel C, Jonkman MF, Horváth B.

Br J Dermatol. 2016 Jun;174(6):1392-4. doi: 10.1111/bjd.14371. Epub 2016 Mar 2. No abstract available.

PMID:
26707687
18.

Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum.

Blok JL, Li K, Brodmerkel C, Horvátovich P, Jonkman MF, Horváth B.

Br J Dermatol. 2016 Apr;174(4):839-46. doi: 10.1111/bjd.14338. Epub 2016 Jan 27.

PMID:
26641739
19.

Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study.

Silkoff PE, Strambu I, Laviolette M, Singh D, FitzGerald JM, Lam S, Kelsen S, Eich A, Ludwig-Sengpiel A, Hupp GC, Backer V, Porsbjerg C, Girodet PO, Berger P, Leigh R, Kline JN, Dransfield M, Calhoun W, Hussaini A, Khatri S, Chanez P, Susulic VS, Barnathan ES, Curran M, Das AM, Brodmerkel C, Baribaud F, Loza MJ.

Respir Res. 2015 Nov 17;16:142. doi: 10.1186/s12931-015-0299-y.

20.

Group-based variant calling leveraging next-generation supercomputing for large-scale whole-genome sequencing studies.

Standish KA, Carland TM, Lockwood GK, Pfeiffer W, Tatineni M, Huang CC, Lamberth S, Cherkas Y, Brodmerkel C, Jaeger E, Smith L, Rajagopal G, Curran ME, Schork NJ.

BMC Bioinformatics. 2015 Sep 22;16:304. doi: 10.1186/s12859-015-0736-4.

21.

Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris.

Chiricozzi A, Suárez-Fariñas M, Fuentes-Duculan J, Cueto I, Li K, Tian S, Brodmerkel C, Krueger JG.

Br J Dermatol. 2016 Jan;174(1):136-45. doi: 10.1111/bjd.14034. Epub 2015 Nov 11.

22.

Histological Stratification of Thick and Thin Plaque Psoriasis Explores Molecular Phenotypes with Clinical Implications.

Kim J, Nadella P, Kim DJ, Brodmerkel C, Correa da Rosa J, Krueger JG, Suárez-Fariñas M.

PLoS One. 2015 Jul 15;10(7):e0132454. doi: 10.1371/journal.pone.0132454. eCollection 2015.

23.

Levels of circulating MMP-7 degraded elastin are elevated in pulmonary disorders.

Kristensen JH, Larsen L, Dasgupta B, Brodmerkel C, Curran M, Karsdal MA, Sand JM, Willumsen N, Knox AJ, Bolton CE, Johnson SR, Hägglund P, Svensson B, Leeming DJ.

Clin Biochem. 2015 Nov;48(16-17):1083-8. doi: 10.1016/j.clinbiochem.2015.07.009. Epub 2015 Jul 9.

PMID:
26164539
24.

Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis.

Judson MA, Baughman RP, Costabel U, Drent M, Gibson KF, Raghu G, Shigemitsu H, Barney JB, Culver DA, Hamzeh NY, Wijsenbeek MS, Albera C, Huizar I, Agarwal P, Brodmerkel C, Watt R, Barnathan ES.

Eur Respir J. 2014 Nov;44(5):1296-307. doi: 10.1183/09031936.00000914. Epub 2014 Jul 17.

25.

Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.

Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, Li K, Campbell K, Marciniak SJ Jr, Wasfi Y, Wang Y, Szapary P, Krueger JG.

J Allergy Clin Immunol. 2014 Apr;133(4):1032-40. doi: 10.1016/j.jaci.2014.01.025.

26.

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials.

Kavanaugh A, Ritchlin C, Rahman P, Puig L, Gottlieb AB, Li S, Wang Y, Noonan L, Brodmerkel C, Song M, Mendelsohn AM, McInnes IB; PSUMMIT-1 and 2 Study Groups.

Ann Rheum Dis. 2014 Jun;73(6):1000-6. doi: 10.1136/annrheumdis-2013-204741. Epub 2014 Feb 19.

27.

Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use.

Brodmerkel C, Wadman E, Langley RG, Papp KA, Bourcier M, Poulin Y, Ho V, Guenther L, Kunynetz R, Nigen S, Vender R, Wasel N, Hsu MC, Szapary P.

J Drugs Dermatol. 2013 Oct;12(10):1122-9.

PMID:
24085047
28.

Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis.

Mehta NN, Li K, Szapary P, Krueger J, Brodmerkel C.

J Transl Med. 2013 Aug 22;11:194. doi: 10.1186/1479-5876-11-194.

29.

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK; PSUMMIT 1 Study Group.

Lancet. 2013 Aug 31;382(9894):780-9. doi: 10.1016/S0140-6736(13)60594-2. Epub 2013 Jun 13.

PMID:
23769296
30.

Meta-analysis derived (MAD) transcriptome of psoriasis defines the "core" pathogenesis of disease.

Tian S, Krueger JG, Li K, Jabbari A, Brodmerkel C, Lowes MA, Suárez-Fariñas M.

PLoS One. 2012;7(9):e44274. doi: 10.1371/journal.pone.0044274. Epub 2012 Sep 5.

31.

Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update.

Yeilding N, Szapary P, Brodmerkel C, Benson J, Plotnick M, Zhou H, Goyal K, Schenkel B, Giles-Komar J, Mascelli MA, Guzzo C.

Ann N Y Acad Sci. 2012 Aug;1263:1-12. doi: 10.1111/j.1749-6632.2012.06670.x. Epub 2012 Jul 23. Review.

PMID:
22823582
32.

Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis.

Suárez-Fariñas M, Li K, Fuentes-Duculan J, Hayden K, Brodmerkel C, Krueger JG.

J Invest Dermatol. 2012 Nov;132(11):2552-64. doi: 10.1038/jid.2012.184. Epub 2012 Jul 5. Erratum in: J Invest Dermatol. 2015 Nov;135(11):2901-2.

33.

Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis.

Richards TJ, Kaminski N, Baribaud F, Flavin S, Brodmerkel C, Horowitz D, Li K, Choi J, Vuga LJ, Lindell KO, Klesen M, Zhang Y, Gibson KF.

Am J Respir Crit Care Med. 2012 Jan 1;185(1):67-76. doi: 10.1164/rccm.201101-0058OC. Erratum in: Am J Respir Crit Care Med. 2012 Feb 15;185(4):464.

34.

Molecular profiling and gene expression analysis in cutaneous sarcoidosis: the role of interleukin-12, interleukin-23, and the T-helper 17 pathway.

Judson MA, Marchell RM, Mascelli M, Piantone A, Barnathan ES, Petty KJ, Chen D, Fan H, Grund H, Ma K, Baribaud F, Brodmerkel C.

J Am Acad Dermatol. 2012 Jun;66(6):901-10, 910.e1-2. doi: 10.1016/j.jaad.2011.06.017. Epub 2011 Sep 15. Review.

PMID:
21924794
35.

Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab.

Benson JM, Sachs CW, Treacy G, Zhou H, Pendley CE, Brodmerkel CM, Shankar G, Mascelli MA.

Nat Biotechnol. 2011 Jul;29(7):615-24. doi: 10.1038/nbt.1903.

PMID:
21747388
36.

Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis.

Loza MJ, Brodmerkel C, Du Bois RM, Judson MA, Costabel U, Drent M, Kavuru M, Flavin S, Lo KH, Barnathan ES, Baughman RP.

Clin Vaccine Immunol. 2011 Jun;18(6):931-9. doi: 10.1128/CVI.00337-10. Epub 2011 Apr 20.

37.

Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives.

Yeilding N, Szapary P, Brodmerkel C, Benson J, Plotnick M, Zhou H, Goyal K, Schenkel B, Giles-Komar J, Mascelli MA, Guzzo C.

Ann N Y Acad Sci. 2011 Mar;1222:30-9. doi: 10.1111/j.1749-6632.2011.05963.x. Review.

PMID:
21434940
38.

Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.

Xue CB, Wang A, Meloni D, Zhang K, Kong L, Feng H, Glenn J, Huang T, Zhang Y, Cao G, Anand R, Zheng C, Xia M, Han Q, Robinson DJ, Storace L, Shao L, Li M, Brodmerkel CM, Covington M, Scherle P, Diamond S, Yeleswaram S, Vaddi K, Newton R, Hollis G, Friedman S, Metcalf B.

Bioorg Med Chem Lett. 2010 Dec 15;20(24):7473-8. doi: 10.1016/j.bmcl.2010.10.020. Epub 2010 Oct 13.

PMID:
21036044
39.

Effects of ustekinumab administration on primate/human antigen-recall and humoral immune response functions.

Brodmerkel C, Zhu Y, Jiao Q, Cornacoff J, Treacy G, Mascelli MA, Gottlieb AB.

J Drugs Dermatol. 2010 Jun;9(6):677-83.

PMID:
20645530
40.

Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters.

Reddy M, Torres G, McCormick T, Marano C, Cooper K, Yeilding N, Wang Y, Pendley C, Prabhakar U, Wong J, Davis C, Xu S, Brodmerkel C.

J Dermatol. 2010 May;37(5):413-25. doi: 10.1111/j.1346-8138.2010.00802.x.

PMID:
20536646
41.

Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases.

Elliott M, Benson J, Blank M, Brodmerkel C, Baker D, Sharples KR, Szapary P.

Ann N Y Acad Sci. 2009 Dec;1182:97-110. doi: 10.1111/j.1749-6632.2009.05070.x. Review.

PMID:
20074279
42.

Simultaneous detection of eight analytes in human serum by two commercially available platforms for multiplex cytokine analysis.

Toedter G, Hayden K, Wagner C, Brodmerkel C.

Clin Vaccine Immunol. 2008 Jan;15(1):42-8. Epub 2007 Nov 14.

43.

Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344.

Brodmerkel CM, Huber R, Covington M, Diamond S, Hall L, Collins R, Leffet L, Gallagher K, Feldman P, Collier P, Stow M, Gu X, Baribaud F, Shin N, Thomas B, Burn T, Hollis G, Yeleswaram S, Solomon K, Friedman S, Wang A, Xue CB, Newton RC, Scherle P, Vaddi K.

J Immunol. 2005 Oct 15;175(8):5370-8.

44.

Transgenic animals in inflammatory disease models.

Brodmerkel CM, Vaddi K.

Curr Opin Biotechnol. 2003 Dec;14(6):652-8. Review.

PMID:
14662397

Supplemental Content

Loading ...
Support Center